10,635 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by DNB Asset Management AS

DNB Asset Management AS acquired a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,635 shares of the company’s stock, valued at approximately $221,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Structure Therapeutics in the second quarter valued at $399,000. Good Life Advisors LLC boosted its position in shares of Structure Therapeutics by 15.4% in the 2nd quarter. Good Life Advisors LLC now owns 15,000 shares of the company’s stock worth $311,000 after buying an additional 2,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Structure Therapeutics by 18.5% in the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after acquiring an additional 8,444 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after acquiring an additional 994 shares in the last quarter. Finally, Quinn Opportunity Partners LLC raised its position in Structure Therapeutics by 90.9% during the second quarter. Quinn Opportunity Partners LLC now owns 42,000 shares of the company’s stock worth $871,000 after acquiring an additional 20,000 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Stock Up 0.1%

GPCR stock opened at $34.22 on Thursday. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -28.05 and a beta of -1.63. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $13.22 and a 52-week high of $40.29. The stock’s fifty day simple moving average is $30.09 and its 200-day simple moving average is $23.83.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Guggenheim lowered their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. JMP Securities lowered their target price on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. Zacks Research cut Structure Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. HC Wainwright decreased their price objective on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Lifesci Capital raised shares of Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $68.67.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.